Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus
Amylyx Pharmaceuticals NASDAQ: AMLX is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the third quarter, Co-Chief Executive Officer Joshua Cohen said at the BofA Annual Healthcare Conference.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC
Ally Bridge Group NY LLC acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 437,391 shares of the company's stock, valued at approximately $5,944,000. Amylyx Pharmaceuticals makes up approximately 3.6%
Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Alpha Wave Global LP
Alpha Wave Global LP increased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) by 18.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 327,312 shares of the company's stock after acquiring an additional 51,470 shares during the period. Amylyx Pharmaceuticals
Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
Amylyx Pharmaceuticals (AMLX) is downgraded from 'Strong Buy' to 'Buy' following the discontinuation of AMX0035 for PSP. Company's investment thesis now centers on avexitide, a GLP-1 receptor antagonist in phase 3 LUCIDITY for post-bariatric hypoglycemia, with topline data expected Q3 2026. The company maintains a strong cash position [$317M, funding into 2028], supporting key milestones including potential avexitide commercialization.
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lindsey Allen Justin Klee - Co-Founder, Co-CEO & Director Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Founder, Co-CEO & Director Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Joseph Thome - TD Cowen, Research Division Kevin Strang - Goldman Sachs Group, Inc., Research Division Marc Goodman - Leerink Partners LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Christopher Chen - Robert W. Baird & Co. Incorporated, Research Division Susan Chor Ananda Ghosh - H.C.
What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now?
Does Amylyx Pharmaceuticals, Inc. (AMLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 29.28% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?
The mean of analysts' price targets for Amylyx Pharmaceuticals (AMLX) points to a 29.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is AMLX Stock a Solid Choice Right Now?
Amylyx has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
